In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders
详细信息 查看全文
- 作者：Linda M. Rorick-Kehn ; Bryan G. Johnson ; Karen M. Knitowski ; Craig R. Salhoff ; Jeffrey M. Witkin ; Kenneth W. Perry ; Kelly I. Griffey ; Joseph P. Tizzano ; James A. Monn and David L. McKinzie ; et al.
- 关键词：Metabotropic glutamate (mGlu) receptors ; mGlu2/3 receptor agonist ; Anxiety ; Schizophrenia ; Psychiatric disorders ; Animal models ; Anxiolytic ; Antipsychotic
- 刊名：Psychopharmacology
- 出版年：2007
- 出版时间：July, 2007
- 年：2007
- 卷：193
- 期：1
- 页码：121-136
- 全文大小：730 KB
- 刊物类别：Biomedical and Life Sciences
- 刊物主题：Biomedicine
Pharmacology and Toxicology
Psychiatry - 出版者：Springer Berlin / Heidelberg
- ISSN：1432-2072
文摘
Rationale Data from both preclinical and clinical studies have provided proof of concept that modulation of limbic and forebrain glutamate, via mGlu2/3 receptor agonists, might provide therapeutic benefits in many psychiatric disorders including schizophrenia and anxiety.